Expanding Partnerships in Single-Domain Antibody (VHH) Innovation

As we step into 2025, AlpalifeBio is excited to expand our co-development opportunities and out-licensing options in the field of single-domain antibody (VHH) discovery. Our goal is to build strategic partnerships with pharmaceutical companies, biotech firms, and university research teams to accelerate scientific innovation and antibody-based solutions.

Why Collaborate with AlpalifeBio?

✅ Leading Experts in VHH Antibody Discovery
With over eight years of experience and more than 1,000 successful collaborations, we specialize in high-quality VHH antibody generation for therapeutic, diagnostic, and industrial applications.

✅ Comprehensive Single-Domain Antibody Development
Our proprietary immunization platform, with a herd of 1,000+ naïve alpacas, ensures the discovery of high-affinity VHH antibodies tailored to specific targets.

✅ Flexible Licensing & Co-Development Models
Whether you seek custom VHH discovery, contract research, or wish to license novel single-domain antibodies, we offer tailored solutions to fit your needs.

✅ Bridging Science & Application
We help transform early-stage research into real-world biopharmaceutical solutions, supporting drug discovery, targeted therapies, and precision medicine.

Who Should Reach Out?

Pharmaceutical & Biotech Companies – Looking for a reliable partner to develop VHH-based therapeutics? Let's innovate together!

University & Research Institutes – Exploring novel targets for single-domain antibodies? We are open to collaborative projects and providing our expertise to academic teams.

AlpalifeBio is committed to advancing antibody research and creating impactful biotechnological solutions. If you're interested in partnering with a leading VHH antibody discovery company, let's talk! 
Contact us today to explore co-development and licensing opportunities in single-domain antibody (VHH) innovation.